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Abstract: Accumulating evidence suggests that metformin, used as an antidiabetic drug, possesses
anti-cancer properties. Metformin reduced the incidence and growth of experimental tumors
in vivo. In a randomized clinical trial among nondiabetic patients, metformin treatment significantly
decreased the number of aberrant crypt foci compared to the untreated group with a follow-up
of 1 month. In our study, HT29 cells were treated with graded concentrations of metformin,
10 mM/25 mM/50 mM for 24/48 h. We performed immunofluorescence experiments by means
of confocal microscopy and western blot analysis to evaluate a panel of factors involved in
apoptotic/autophagic processes and oxidative stress response. Moreover, HT29 cells treated with
metformin were analyzed by a flow cytometry assay to detect the cell apoptotic rate. The results
demonstrate that metformin exerts growth inhibitory effects on cultured HT29 cells by increasing
both apoptosis and autophagy; moreover, it affects the survival of cultured cells inhibiting the
transcriptional activation of Nuclear factor E2-related factor 2 (NRF-2) and nuclear factor-kappa B
(NF-κB). The effects of metformin on HT29 cells were dose- and time-dependent. These results are
very intriguing since metformin is emerging as a multi-faceted drug: It has a good safety profile and
is associated with low cost and might be a promising candidate for the prevention or the treatment of
colorectal cancer.
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1. Introduction
Colorectal cancer (CRC) is still a major neoplasm [1], and its prevalence and mortality have a
high impact on human health [2]. A paradigm shift from surveillance and early detection of cancer
or adenomas to new preventive strategies, including chemoprevention, is necessary to lower the
burden of this disease. Several large epidemiologic and clinical studies have evaluated the possible
effects of more than 200 agents, including fibers, calcium, and nonsteroidal anti-inflammatory drugs
such as 5-aminosalicylic acid and selective cyclooxygenase-2 (COX-2) inhibitors, in preventing CRC
development [3]. Nonsteroidal anti-inflammatory drugs, especially COX-2 inhibitors alone or in
combination, have shown the most promise for CRC risk reduction [4], but an increased risk of
serious cardiovascular events associated with COX-2 inhibitor use has been reported [5,6]. Thus,
novel drugs that would be both safe and effective are needed for CRC prevention. CRC is associated
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with lifestyle-related diseases such as diabetes and obesity [7–10]; these conditions might represent new
targets for CRC chemoprevention. Metformin (1, 1-dimethylbiguanide hydrochloride) is a biguanide
derivative that has been extensively used for treating diabetes mellitus [11]. It decreases basal glucose
output by suppressing gluconeogenesis and glycogenolysis in the liver, and by increasing glucose
uptake in muscle tissue. Because metformin does not directly stimulate insulin secretion, the risk
of hypoglycemia associated with its use is lower than that associated with the use of other oral
antidiabetic drugs [12]. The mechanism of action of metformin involves liver kinase B1–dependent
activation of AMP-activated protein kinase [13]. Patients with type 2 diabetes taking metformin might
be at a lower risk of cancer (including CRC), compared with those who do not take metformin [14,15].
This evidence suggests that metformin might be a candidate agent for the chemoprevention of CRC in
diabetic patients. In a number of preclinical studies, metformin reduced cell proliferation, induced
apoptosis, caused cell cycle arrest, and reduced incidence and growth of experimental tumors in vitro
and in vivo [16,17]. Some reports also indicate that metformin improved the response of human breast
tumor xenografts to conventional chemotherapy by eradicating cancer stem cells in the tumor [18,19].
HT-29 is a human colorectal adenocarcinoma cell line with epithelial morphology and represents a
xenograft tumor model for colorectal cancer. Nuclear factor E2-related factor 2 (NRF-2) is a transcription
factor that controls the expression of a large pool of antioxidant and cytoprotective genes regulating the
cellular response to oxidative and electrophilic stress. Mutations in the NRF-2 gene, common in cancer
cells, could help tumor cells to survive, and might be associated with poor survival of cancer patients.
Previous studies have shown that the NRF-2 signaling pathway is abnormally activated in CRC. NF-κB
plays a major role in linking inflammation to cancer development through its ability to upregulate
several inflammatory and tumor promoting cytokines, such as IL-6, IL-1α, and Tumor Necrosis Factor
α (TNFα), as well as genes like BCL2 and BCLXL. Furthermore, NF-κB plays an important role in type
2 diabetes mellitus (T2DM), as obesity activates the transcription factor NF-κB, which increases the
risk for T2DM. Collectively, NF-κB could be considered as the matchmaker between inflammation,
inflammatory bowel diseases (IBD), cancer, and diabetes [20]. The present study aims to assess whether
metformin has the potential to suppress the growth of colorectal cancer cells and to evaluate its role in
affecting the NRF-2/NF-κB pathways.
2. Results
2.1. Metformin Suppresses the Proliferation of HT29 Cells in a Dose- and Time-Dependent Manner
In order to examine whether metformin affects human colorectal cancer cell proliferation,
we investigated the effect of the drug on the cancer cell line HT29 cells. Cells were grown in 10% fetal
bovine serum (FBS) and treated with increasing amount of metformin (0, 10, 25, and 50 mmol/L).
The immunofluorescence analysis was performed after the addition of the agents for 24 and 48 h,
to characterize the time-dependent impacts of metformin.
The first observation was made using an inverted microscope and raised concerns about the
eventual changes of some features (viability, adhesion, and morphology) of the treated cells compared
to controls; as shown in Figure 1 the phenotype of HT29 cells treated with metformin was preserved,
although the cell adhesion to the culture plates implied some changes in the characteristic rounded
shape of untreated HT29 cells Figure 1.
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Figure 1. Inverted microscope image of HT29 cells treated with graded concentrations of metformin, 
10 mM/25 mM/50 mM for 24 h and 48 h; and of untreated cells (CTRL). The phenotype of HT29 cells 
treated with metformin was preserved, although cell adhesion to the culture plates caused some 
changes in the characteristic rounded shape of untreated HT29 cells. Magnification 40×. 
This modification of cell morphology is probably due to the partial loss of plasma membrane 
attachment, these features are characteristic of the earliest phases of the apoptotic process. Cell 
counting showed that metformin caused a strong anti-proliferative effect at a dose of 10 mM for 24 
h; the effect was slight, but significant anti-proliferative action was observed with higher doses for 24 
h or 48 h. The counting obtained was the following, 43%, 52%, and 65% inhibition for 10 mM, 25 mM, 
and 50 mM, respectively, compared with controls after 24 h treatment; 45%, 61%, and 68% inhibition 
for 10 mM, 25 mM, and 50 mM, respectively, compared with controls after 48 h treatment. 
To confirm these preliminary data, immunofluorescence experiments, coupled with confocal 
analysis, were performed using a panel of antibodies to determine the effect of metformin treatment 
on the expression profile of autophagy/apoptosis or proliferation markers. 
The Ki-67 protein was used as a marker for cell proliferation and the results from the 
immunofluorescence analysis Figure 2, and showed that metformin significantly downregulates the 
expression of Ki-67 and nuclear localization in a time- and dose-dependent manner. 
The treatment at 48 h with MET 50 mM caused a maximum decrease of 45% in the proliferation 
index, as reported in Table 1, which collects data of semi-quantitative evaluation of immunostaining 
intensity (Immunofluorescence Intensity Score: IFIS). 
  
Figure 1. Inverted microscope image of HT29 cells treated with graded concentrations of metformin,
10 mM/25 mM/50 mM for 24 h and 48 h; and of untreated cells (CTRL). The phenotype of HT29
cells treated with metformin was preserved, although cell adhesion to the culture plates caused some
changes in the characteristic rounded shape of untreated HT29 cells. Magnification 40×.
This odification of cell morphology is probably due to the partial loss of plasma membrane
attachment, these features are characteristic of the earliest phases of the apoptotic process. Cell counting
showed that metformin caused a strong anti-proliferative effect at a dose of 10 mM for 24 h; the effect
was slight, but significant anti-proliferative action was observed with higher doses for 24 h or 48 h.
The counting obtained was the following, 43%, 52%, and 65% inhibition for 10 mM, 25 mM, and 50 mM,
respectively, compared with controls after 24 h treatment; 45%, 61%, and 68% inhibition for 10 mM,
25 mM, and 50 mM, respectively, compared with controls after 48 h treatment.
To confirm these preliminary d ta, immunofluorescence experiments, coupled with confocal
analysis, were performed using a panel of antibodies to determine the effect of metformin treatment
on the expression profile of autophagy/apoptosis or proliferation markers.
The Ki-67 protein was used as a marker for cell proliferation and the results from the
immunofluorescence analysis Figure 2, and showed that metformin significantly downregulates
the expression of Ki-67 and nuclear localization in a time- and dose-dependent manner.
The treatment at 48 h with MET 50 mM caused a maximum decrease of 45% in the proliferation
index, as reported in Table 1, which collects data of semi-quantitative evaluation of immunostaining
intensity (Immunofluorescence Intensity Score: IFIS).
Table 1. Evaluation of immunostaining intensity (Immunofluorescence Intensity Score: IFIS).
Proteins
IFIS (Mean± SD)-24 h IFIS (mean± SD)-48 h
CTRL 10 mM 25 mM 50 mM CTRL 10 mM 25 mM 50 mM
PARP-1 20.0 ± 4.3 47.0 ± 11.0 63.0 ± 9.8 76.0 ± 15.0 23.0 ± 12.0 55.0 ± 6.7 74.0 ± 13.0 89.0 ± 22.0
Caspase-3 36.0 ± 9.5 49.0 ± 23.0 69.0 ± 15.0 91.0 ± 7.4 32.0 ± 5.7 64.0 ± 17.0 97.0 ± 20.0 101.0 ± 29.0
APAF-1 31.0 ± 7.5 54.0 ± 3.9 66.0 ± 19.0 85.0 ± 9.5 27.0 ± 7.0 72.0 ± 17.0 72.0 ± 17.0 93.0 ± 12.0
MAP-LC3 26.0 ±4.7 45.0 ± 7.2 71.0 ± 7.6 93.0 ± 15.0 28.0 ± 8.3 57.0 ± 6.3 84.0 ± 5.4 103.0 ± 32.0
NRF-2 55.0 ± 7.2 43.0 ± 6.3 31.0 ± 4.8 19.0 ± 3.7 63.0 ± 12.0 47.0 ± 5.4 30.0 ± 7.5 23.0 ± 3.0
NF-κB 60.0 ± 9.5 54.0 ± 8.3 47.0 ± 15.0 32.0 ± 7.4 67.0 ± 5.7 50.0 ± 17.0 33.0 ± 2.0 25.0 ± 2.9
p < 0.05 between all group pairs.
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Figure 2. Confocal analysis of Ki-67 protein in treated and untreated cells with graded concentrations 
of metformin (blue: DAPI; Green: Ki-67; (C,F): merge). Cells that were treated with 10 mM MET for 48 
h showed a weak immunostaining at the nuclear level (A–C), whereas untreated cells resulted very 
marked (D–F). Scale bar = 8 µm. 
Furthermore, immunofluorescence analysis was conducted using apoptotic and autophagic 
specific markers in order to determine whether the inhibitory effect of metformin on colorectal cancer 
cells was associated with triggering programmed cell death or autophagy. 
Using these techniques, we evaluated both qualitatively and quantitatively Cleaved PARP-1, 
APAF-1, Caspase-3, and MAPLC3 protein expression. Figure 3 shows the co-immunostaining of 
Cleaved PARP-1 and Caspase-3. 
Figure 2. Confocal analysis of Ki-67 protein in treated and untreated cells with graded concentrations
of metformin (blue: DAPI; Green: Ki-67; (C,F): merge). Cells that were treated with 10 mM MET for
48 h showed a weak immunostaining at the nuclear level (A–C), whereas untreated cells resulted very
marked (D–F). Scale bar = 8 µm.
Furthermore, im unofluorescence analysis as conducted using apoptotic and autophagic
specific markers in order to determine whether the inhibitory effect of metformin on colorectal cancer
cells was associated with triggering programmed cell death or autophagy.
Using these techniques, we evaluated both qualitatively and quantitatively Cleaved PARP-1,
APAF-1, Caspase-3, and MAPLC3 protein expression. Figure 3 shows the co-immunostaining of
Cleaved PARP-1 and Caspase-3.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  5 of 17 
 
 
Figure 3. Confocal analysis of PARP-1 and Caspase-3 active proteins in treated and untreated cells with 
different concentrations of metformin (blue: DAPI; Red: PARP-1 Green: Caspase-3 active; (D,H,L): 
merge). Cells that were treated with 10 mM MET for 24 h showed a strong immunostaining for both 
proteins (A–D), as well as cells treated with 25 mM MET for 24 h (E–H). Untreated cells showed a 
significant decrease in PARP-1 and Caspase-3 active protein expression (I–L). Scale bar = 15 µm. 
Cleaved PARP-1 antibody detects endogenous levels of the large fragment (89 KDa) of the 
human protein resulting from cleavage of the native protein and does not recognize the full length 
PARP-1 or other isoforms. Cleaved PARP-1 was detectable in the nucleus of treated HT-29 cells; 
however, it is not appreciable in untreated cells Figure 3K. Some representative staining patterns are 
shown in Figure 3A–D where nuclear labeling of apoptotic cells is evident, as revealed by DAPI 
staining. Caspase-3 was aggregated in small clumps distributed in the cytoplasm of cultured treated 
cells, both proteins showed an increased expression pattern related to the dose and time of metformin 
treatment, as shown in Figure 3A–H. Untreated cells were negative for immunostaining Figure 3I–L. 
Figure 4 shows the immunostaining of APAF-1 and MAPLC3. 
The staining patterns of the first protein varied from diffuse to granular in the nucleus of treated 
cells; on the other hand, cells expressing MAPLC3 protein showed two distinct autophagic patterns: 
diffuse fine and granular reactivity was dispersed in the cytoplasm, or a rounded densely stained 
material, which was probably enclosed within a cytoplasmic vacuole that accumulates prevalently 
around the nucleus (Figure 4G–I). 
The dense rounded autophagic vacuoles were well recognizable in cells treated with higher 
doses and for longer time; such structures varied in size and density, but usually formed coarse, 
rather than fine, granules. Untreated cells showed a weak marking for both proteins Figure 4D–F,J–L. 
The semiquantitative evaluation of immunostaining intensity, reported as the 
Immunofluorescence Intensity Score (IFIS) in Table 1, showed that the level of cleaved PARP-1, 
Caspase-3, APAF-1, and MAPLC3 proteins had an increasing trend in a dose- and time-dependent 
manner, with statistical significance of the different expression among the groups of treated cells, and 
with respect to untreated cells. 
Figure 3. Confocal analysis of PARP-1 and Caspase-3 active proteins in treated and untreated cells
with different concentrations of metformin (blue: DAPI; Red: PARP-1 Green: Caspase-3 active; (D,H,L):
merge). Cells that were treated with 10 mM MET for 24 h showed a strong immunostaining for both
proteins (A–D), as well as cells treated with 25 mM MET for 24 h (E–H). Untreated cells showed a
significant decrease in PARP-1 and Caspase-3 active protein expression (I–L). Scale bar = 15 µm.
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Cleaved PARP-1 antibody detects endogenous levels of the large fragment (89 KDa) of the human
protein resulting from cleavage of the native protein and does not recognize the full length PARP-1
or other isoforms. Cleaved PARP-1 was detectable in the nucleus of treated HT-29 cells; however,
it is not appreciable in untreated cells Figure 3K. Some representative staining patterns are shown
in Figure 3A–D where nuclear labeling of apoptotic cells is evident, as revealed by DAPI staining.
Caspase-3 was aggregated in small clumps distributed in the cytoplasm of cultured treated cells,
both proteins showed an increased expression pattern related to the dose and time of metformin
treatment, as shown in Figure 3A–H. Untreated cells were negative for immunostaining Figure 3I–L.
Figure 4 shows the immunostaining of APAF-1 and MAPLC3.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  6 of 17 
 
 
Figure 4. Confocal analysis of APAF-1 and MAPLC3 proteins in treated and untreated cells with 
different concentrations of metformin (Blue: DAPI; Green: MAPLC3; Red: APAF-1; (C,F,I,L): merge). 
In treated cells with 50 mM MET for 48 h, APAF-1 showed a diffuse or granular staining pattern at 
the nuclear level (A–C), while in untreated cells nuclear expression was barely detectable (D–F). In 
treated cells with 50 mM MET for 48 h MAPLC3 protein there were two distinct autophagic patterns: 
A diffuse finely and granular reactivity dispersed in the cytoplasm, or a rounded densely stained 
material, probably enclosed within a cytoplasmic vacuole that accumulates prevalently around the 
nucleus (G–I); untreated cells were very weakly marked (J–L). Scale bar = 10 µm. 
Moreover, to corroborate the findings of the morphological evaluation previously described, cell 
lysates of cultured treated and untreated cells were subjected to western blot analysis. As shown in 
Figure 5, protein bands immunopositive for APAF-1, Cleaved PARP-1, MAPLC3, and caspase-3 were 
clearly evident in treated cells. 
Figure 4. Confocal analysis of APAF-1 and MAPLC3 proteins in treated and untreated cells with
different concentrations of metformin (Blue: DAPI; Green: MAPLC3; Red: APAF-1; (C,F,I,L): merge).
In treated cells with 50 mM MET for 48 h, APAF-1 showed a diffuse or granular staining pattern
at the nuclear level (A–C), while in untreated cells nuclear expression was barely detectable (D–F).
In treated cells with 50 mM MET for 48 h MAPLC3 protein there were two distinct autophagic patterns:
A diffuse finely and granular reactivity dispersed in the cytoplasm, or a rounded densely stained
material, probably enclosed within a cytoplasmic vacuole that accumulates prevalently around the
nucleus (G–I); untreated cells were very weakly marked (J–L). Scale bar = 10 µm.
The staining patterns of the first protein varied from diffuse to granular in the nucleus of treated
cells; on the other hand, cells expressing MAPLC3 protein showed two distinct autophagic patterns:
diffuse fine and granular reactivity was dispersed in the cytoplasm, or a rounded densely stained
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material, which was probably enclosed within a cytoplasmic vacuole that accumulates prevalently
around the nucleus (Figure 4G–I).
The dense rounded autophagic vacuoles were well recognizable in cells treated with higher doses
and for longer time; such structures varied in size and density, but usually formed coarse, rather than
fine, granules. Untreated cells showed a weak marking for both proteins Figure 4D–F,J–L.
The semiquantitative evaluation of immunostaining intensity, reported as the Immunofluorescence
Intensity Score (IFIS) in Table 1, showed that the level of cleaved PARP-1, Caspase-3, APAF-1,
and MAPLC3 proteins had an increasing trend in a dose- and time-dependent manner, with statistical
significance of the different expression among the groups of treated cells, and with respect to
untreated cells.
Moreover, to corroborate the findings of the morphological evaluation previously described,
cell lysates of cultured treated and untreated cells were subjected to western blot analysis. As shown
in Figure 5, protein bands immunopositive for APAF-1, Cleaved PARP-1, MAPLC3, and caspase-3
were clearly evident in treated cells.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  7 of 17 
 
 
Figure 5. Western blot analysis of HT29 cells treated with graded concentrations of metformin, 10 
mM/25 mM/50 mM for 24 h and 48 h; and of untreated cells (CTRL), using anti-APF-1, PARP-1, 
MAPLC3, and Caspase-3 antibodies. Mean densitometric data of APAF-1, PARP-1, MAPLC3, and 
Caspase-3 expressions were analyzed using NIH Image J software. p < 0.05 between all group pairs. 
Lysates of untreated cells generally yielded only a faint band for all these markers. Densitometric 
analysis and normalization (with equal amounts of protein loading) of the immunoreactivity signals 
from protein extracts of treated and untreated cells showed that the expression pattern had an 
increasing trend related to the dose- and time- of treatment. Western blotting and densitometric 
analysis were performed in triplicate; the quantification of protein expressions between different 
groups of treatment and respect to the untreated group achieved statistical significance. 
2.2. Metformin Alters NRF-2 and NF-κB Expression in HT29 Cells in a Dose- and Time-Dependent Manner 
Confocal analysis was conducted on HT29 cells treated with increasing amount of metformin (0, 
10, 25, and 50 mmol/L), as described above, to analyze the expression pattern of NRF-2 and NF-κB 
proteins. The results demonstrated that metformin affects survival of cultured cells inhibiting the 
transcriptional activation of NRF-2 and NF-κB. In Figure 6A–C the presence of NRF-2 at the nuclear 
level in untreated cells is clearly evident, as a consequence of the translocation of the transcriptional 
factor into the nucleus; in particular, nucleolar domains appeared strongly marked Figure 6B. 
Figure 5. Western blot analysis of HT29 cells tr ated with graded o centrations of metformin,
10 mM/25 mM/50 mM for 24 h and 48 h; and of untreated cells (CTRL), using anti-APF-1, PARP-1,
MAPLC3, and Caspase-3 antibodies. Mean densitometric data of APAF-1, PARP-1, MAPLC3,
and Caspase-3 xpressions were analyzed using N H Image J software. p < 0.05 between all grou pairs.
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Lysates of untreated cells generally yielded only a faint band for all these markers. Densitometric
analysis and normalization (with equal amounts of protein loading) of the immunoreactivity signals
from protein extracts of treated and untreated cells showed that the expression pattern had an
increasing trend related to the dose- and time- of treatment. Western blotting and densitometric
analysis were performed in triplicate; the quantification of protein expressions between different
groups of treatment and respect to the untreated group achieved statistical significance.
2.2. Metformin Alters NRF-2 and NF-κB Expression in HT29 Cells in a Dose- and Time-Dependent Manner
Confocal analysis was conducted on HT29 cells treated with increasing amount of metformin
(0, 10, 25, and 50 mmol/L), as described above, to analyze the expression pattern of NRF-2 and NF-κB
proteins. The results demonstrated that metformin affects survival of cultured cells inhibiting the
transcriptional activation of NRF-2 and NF-κB. In Figure 6A–C the presence of NRF-2 at the nuclear
level in untreated cells is clearly evident, as a consequence of the translocation of the transcriptional
factor into the nucleus; in particular, nucleolar domains appeared strongly marked Figure 6B.
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Figure 6. Confocal analysis of NRF-2 and NF-κB proteins in treated and untreated cells with graded 
concentrations of metformin (Blue: DAPI; Red: NRF-2, and NF-κB; (C,F,I,L): merge). NRF-2 clearly 
showed a strong nuclear reactivity in untreated cells (A–C), whereas in cells treated with 25 mM MET 
for 24 h the reactivity was finely dispersed only in the cytoplasmic compartment (D–F). NF-κB showed 
a significant translocation into the nucleus in untreated cells with 25 mM MET for 24 h (G–I), while in 
treated cells the protein was scattered in the cytoplasm (J–L). Scale bar = 10 µm. 
Treated cells showed a well detectable presence of this protein in the cytoplasm, while the nuclei 
were slightly marked Figure 6D–F. The effects of metformin on HT29 cell were dose- and time-
dependent, because there was a significant change in the parameters analyzed after 48 h of treatment 
compared to 24 h, see Table 1. 
NF-κB protein showed a very intense immunostaining in the nuclear compartment in untreated 
samples, while the cytoplasm was less stained, see Figure 6G–I. In treated cells, the presence of this 
protein was appreciable only in the cytoplasmic compartment and the staining was evenly 
distributed throughout the cell Figure 6J–L. The semi-quantitative evaluation of immunostaining 
intensity (IFIS) in Table 1 showed that the level of NRF-2 and NF-κB proteins had a decreasing trend 
in a dose- and time-dependent manner, with statistical significance of the different expressions 
among the groups of treated cells with respect to the untreated ones. 
Western blot analysis showed that NRF-2 expression decreased after treatment with increasing 
concentrations of metformin. This observation was more evident after 48 h of treatment. The 
expression pattern of NF-κB was slightly different, and the protein amount decreased with higher 
doses of metformin with respect to NRF-2, Figure 7. 
Figure 6. Confocal analysis of NRF-2 and NF-κB proteins in treated and untreated cells with graded
concentrations of metformin (Blue: DAPI; Red: NRF-2, and NF-κB; (C,F,I,L): merge). NRF-2 clearly
showed a strong nuclear reactivity in untreated cells (A–C), whereas in cells treated with 25 mM MET
for 24 h the reactivity w s finely dispersed only in th cytoplasmic compartment (D–F). NF-κB showed
a significant translocatio into the nucleus in untreated cells with 25 mM MET for 24 h (G–I), while in
treated cells the protein was scattered in the cytoplasm (J–L). Scale bar = 10 µm.
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Treated cells showed a well detectable presence of this protein in the cytoplasm, while the
nuclei were slightly marked Figure 6D–F. The effects of metformin on HT29 cell were dose- and
time-dependent, because there was a significant change in the parameters analyzed after 48 h of
treatment compared to 24 h, see Table 1.
NF-κB protein showed a very intense immunostaining in the nuclear compartment in untreated
samples, while the cytoplasm was less stained, see Figure 6G–I. In treated cells, the presence of this
protein was appreciable only in the cytoplasmic compartment and the staining was evenly distributed
throughout the cell Figure 6J–L. The semi-quantitative evaluation of immunostaining intensity (IFIS)
in Table 1 showed that the level of NRF-2 and NF-κB proteins had a decreasing trend in a dose- and
time-dependent manner, with statistical significance of the different expressions among the groups of
treated cells with respect to the untreated ones.
Western blot analysis showed that NRF-2 expression decreased after treatment with increasing
concentrations of metformin. This observation was more evident after 48 h of treatment. The expression
pattern of NF-κB was slightly different, and the protein amount decreased with higher doses of
metformin with respect to NRF-2, Figure 7.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  9 of 17 
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antibodies. Mean densitometric data of NRF-2 and NF-κB expressions were analyzed using NIH 
ImageJ software. p < 0.05 between all group pairs. 
Densitometric analysis and normalization (with equal amounts of protein loading) of the 
immunoreactivity signals from protein extracts of treated and untreated cells showed that the 
expression pattern had a decreasing trend related to the dose and time of treatment. Western blotting 
and densitometric analysis were performed in triplicate; the quantification of protein expressions 
between different groups of treatment and the untreated group achieved statistical significance. 
2.3. Flow Cytometry Analysis Demonstrates That Metformin Exerts an Inhibitory Effect on HT29 Cells 
Survival 
The ability of Metformin treatment to induce apoptosis in HT-29 cells was determined using an 
Annexin V-FITC assay to establish the relationship between antiproliferation and apoptosis. 
Staining with FITC Annexin V clearly showed that the percentage of apoptotic HT29 cells treated 
with metformin increased in a time- and dose-dependent manner, when comparing treatments to 
each other. Similarly, the early apoptotic death rate of the HT-29 cells treated with MET was 
remarkably higher than the controls Figure 8A,B. The highest rate of apoptotic cells (i.e., 60%) was 
achieved with the 50 mM treatment for 48 h, Figure 8B. Flow cytometry analyses were performed in 
Figure 7. Western blot analysis of HT29 cells treated with graded concentrations of metformin,
10 mM/25 mM/50 mM for and 48 h, a d untr ated cells (CTRL), using anti-NRF-2 and anti-
NF-κB antibodies. ean densitometric data of NRF-2 and NF-κB expressions were analyzed using
NIH ImageJ software. p < 0.05 between all group pairs.
Densitometric analysis and normalization (with equal amounts of protein loading) of the
immunoreactivity signals from protein extracts of treated and untreated cells showed that the
expression pattern had a decreasing tre d related to the dose and time of treatment. Western blotting
and densitometric analysis were performed in triplicate; the quantification of protein expressions
between different groups of treatment and the untreated group achieved statistical significance.
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2.3. Flow Cytometry Analysis Demonstrates That Metformin Exerts an Inhibitory Effect on HT29
Cells Survival
The ability of Metformin treatment to induce apoptosis in HT-29 cells was determined using an
Annexin V-FITC assay to establish the relationship between antiproliferation and apoptosis.
Staining with FITC Annexin V clearly showed that the percentage of apoptotic HT29 cells treated
with metformin increased in a time- and dose-dependent manner, when comparing treatments to each
other. Similarly, the early apoptotic death rate of the HT-29 cells treated with MET was remarkably
higher than the controls Figure 8A,B. The highest rate of apoptotic cells (i.e., 60%) was achieved with
the 50 mM treatment for 48 h, Figure 8B. Flow cytometry analyses were performed in triplicate and the
results, which reached statistical significance, agreed with those obtained by the confocal microscopy
analysis and western blot experiments.
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3. Discussion
In this study, HT29 cells were treated with different concentrations of metformin,
10 mM/25 mM/50 mM for 24 and 48 h. We performed immunofluorescence experiments by means
of confocal microscopy and western blot analysis to evaluate a panel of factors involved in
apoptotic/autophagic processes and oxidative stress response. Moreover, HT29 cells treated with
metformin were analyzed by flow cytometry assay to detect the apoptotic rate of the cells. The first
observations concerning the phenotype of HT29 cells treated with metformin showed modifications
of cell morphology, probably due to the partial loss of plasma membrane attachment; these features
are characteristic of the earliest phases of the apoptotic process. The immunofluorescence analysis
of Ki-67 expression pattern corroborates this finding; in fact, there was a strong decrement of Ki-67
protein in treated cells with respect to the untreated ones. All these results were related to dose
and time of treatment. Moreover, the apoptotic-inducing activities of metformin causes an increase
in the early apoptotic death rate that results in poor survival of cells after treatment, as clearly
demonstrated by flow cytometry experiments. Overall, these results show that metformin may not
only inhibit the growth of HT29 cells, but also induces cell apoptosis. These considerations were
supported by the analysis of key factors involved in the apoptotic process as APAF-1, Cleaved PARP-1,
and caspase-3 active. Cell apoptosis is activated in response to both intrinsic and extrinsic pathways.
Drug therapies that induce apoptosis cause DNA damage-induced and p53-regulated release of
cytochrome-c from mitochondria. In turn, cytochrome-c binds to apoptosis-activating factor-1 (APAF-1),
resulting in the activation of caspase 9, which is followed by the activation of effector caspases including
caspase 3. Following ligation, death receptors signal cell death by inducing a death-inducing signaling
complex composed of the cytoplasmic adapter protein FADD (Fas-associated death domain) and
caspase 8. Activated caspase 8 can activate caspase 3 both directly and indirectly by truncation of
Bid [21]. Metformin has been shown to induce cancer cell apoptosis through both the intrinsic and
extrinsic pathways [22]. In this study, we observed that caspase 3 active, Cleaved PARP-1, and APAF-1
expressions were higher in treated cells with respect to untreated cells in a statistically significant
manner, already in the lowest metformin concentration used (10 mmol/L). Previously, metformin
at 20 mmol/L has been shown effective against breast cancer [23], melanoma [24], and gastric
cancer [25]. The concentration of metformin administered to type 2 diabetic patients is approximately
30–60 µmol/L [26]. Thus, the doses of metformin that were shown effective against cancer cells are
approximately 300–600 fold (around 20 mmol/L) greater than the dose routinely administered for
diabetic disorders, and about 1000 times higher than what is used in common practice [27]. In this
study, we used also a low dose of metformin (10 mmol/L) in order to establish whether the drug
induces apoptosis at doses that avoid toxic side effects to cells. The results confirmed that metformin
was effective even at low doses, whereas higher metformin concentrations, being toxic, will lead to
apoptosis. Furthermore, for anticancer metformin translational research the metformin concentration
obviously needs to change. Elevated levels of autophagic marker expression were observed in treated
cells. This result may have controversial interpretations, in fact recent studies suggest that autophagy
plays a dual role in determining cell fate, which means that it could be a survival mechanism or induce
programmed cell death, depending on different cellular stresses. In some conditions, the activation of
autophagy provides cell protection presumably by eliminating dysfunctional organelles and proteins
and maintaining the energy balance. To a large extent, the cytoprotective function of autophagy appears
to be a consequence of the fact that autophagy induction inhibits apoptosis through a cross-talk between
autophagy and apoptosis regulatory pathways. On the other hand, autophagy is also considered a
type of cell death program [28]. It is well known that there are 3 types of cell death. Necrosis, a type of
unprogrammed cell death, evokes cellular inflammation reaction by immunological activation and
subsequently leads to cell death in neighbor cells. Apoptosis, which is programmed cell death type I,
is characterized by the formation of chromatin condensation, DNA fragmentation, and apoptotic bodies.
Cell death by overactivated autophagy has been referred to as programmed cell death type II [29].
Upregulation of autophagy has been shown to lead to cell death in order to eliminate damaged or
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abnormal cells. It would seem reasonable to expect that cytotoxic autophagy should be a consequence
of higher levels or a more prolonged process of cellular self-digestion rather than of cytoprotective
autophagy. However, there is no explicit experimental evidence suggesting that cytotoxic autophagy is
uniquely different from cytoprotective autophagy. In general, depending on the type of the tumor and
stimuli, as well as the extent of DNA damage, autophagy can have both cytoprotective and cytotoxic
functions [30].
Another point to be discussed is the response of NRF-2 protein to metformin treatment; the NRF-2
expression profile is negatively regulated by the drug in a dose- and time-dependent manner.
This finding is very intriguing as there are researches geared towards defining the boundaries between
NRF-2 positive and negative effects in cancer, which aim to establish a precise rationale for undertaking
NRF-2 therapeutic targeting. The main function of the transcription factor NRF-2 is to activate the
cellular antioxidant response by inducing the transcription of several genes to protect cells from the
effects of exogenous and endogenous insults such as xenobiotics and oxidative stress [31]. As a result,
NRF-2 has been typically regarded as a cytoprotective transcription factor and is considered as the
main defense mechanism of the cell and a major regulator of cell survival. Thus, NRF-2 has been
traditionally deemed to be a tumor suppressor. Indeed, NRF-2-deficient mice are more sensitive
to carcinogenesis [32,33] and NRF-2 loss has been linked to enhanced metastatic potential [34,35].
However, in the past few years, increasing evidence suggest that NRF-2 activation might not be
beneficial in all cancer types and stages. In fact, NRF-2 promotes survival not only of normal cells but
also of cancer cells, supporting the hypothesis that NRF-2 activation in malignant cells might sustain the
evolution of the disease. The identification of a ‘dark side’ of NRF-2 [36,37] has generated controversy
because it is still unclear whether NRF-2 acts as a tumor suppressor or as an oncogene [36,38]. Indeed,
since oxidative stress is involved in the initiation of cancer, the anti-oxidative function of NRF-2 may
play an anticancer role and may be useful in cancer chemoprevention. NRF-2 hyperactivation in tumors
creates an environment that may favor the survival of cancer cells by protecting them from excessive
oxidative stress, chemotherapeutic agents, or radiotherapy [31,39,40]. Indeed, in human tumor samples
and cell lines, constitutive NRF-2 activation increases the expression of some genes involved in
drug metabolism, thereby sustaining resistance to chemotherapeutic drugs and radiotherapy [41].
NRF-2 can play an important role in chemoresistance, preventing the intracellular accumulation of
drugs in cancer cells and subsequently protecting cells from apoptosis [42]. These literature data
are in line with our observation that metformin induces an increase of apoptotic key-factors and
reduces the nuclear translocation of NRF-2 protein. To our knowledge, this is the first study in which
the effect of metformin on NRF-2 protein is investigated, and it may provide an opportunity to
study new molecules capable of interfering with the binding and activation of the NRF-2 pathway.
Moreover, NF-κB expression pattern is drastically affected by metformin treatment, in fact, treated
cells showed a significant decrease in NF-κB protein levels. In addition, the protein was present
only in the cytoplasmic compartment, whereas, in untreated cells NFκB was expressed at the nuclear
level. Several lines of evidence have shown that the transcription factor, nuclear factor-kappa B
(NF-κB), is a critical determinant, as it regulates a variety of pathophysiological processes, such as
inflammation, cell survival, proliferation, invasion, apoptosis, differentiation, and chemo-resistance
in different tumor cells, including colorectal [43,44]. Therefore, pharmacologically-safe antitumor
agents with potential to influence the tumor microenvironment and inhibit NF-κB signaling activation
may enhance chemo-sensitivity and reduce metastasis of tumor cells, thus providing a promising
approach for the prevention or treatment of tumors. Moreover, several studies are posing NF-κB as a
key regulator in the cross-talk among the pathways leading to type 2 diabetes mellitus, inflammatory
bowel diseases, and colorectal cancer [20]. Actually, various carcinogens, growth factors, inflammatory
stimuli including microbiota and pro-oxidants activate the transcription factor NF-κB which plays
a central role in inflammation and is mostly expressed in cancers [45]. NF-κB plays a pivotal role
in linking chronic inflammation to cancer development through its ability to upregulate several
inflammatory and tumor promoting cytokines such as IL-6, IL-1α, and TNF-α, as well as survival genes
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such as BCL2 and BCLXL [46]. In addition, NF-κB promotes the epithelial–mesenchymal transition
(EMT), through activation of snail and twist [47] in the microenvironment, and the expression of
inflammatory cytokines. Moreover, NF-κB seems to be involved in tumor-associated macrophage
(TAM) recruitment and acts in cancer-associated fibroblasts (CAF), by promoting the expression of a
proinflammatory gene signature, which is important for macrophage recruitment, neovascularization,
and tumor growth, which are abolished when NF-κB is inhibited [48] This study shows that metformin
has an antiproliferative effect related to changes in the expression of NRF-2/NF-κB pathways, as well
as an apoptotic effect on human colon cancer cells. Although further studies are needed to elucidate the
detailed correlation between these processes, it can be hypothesized that metformin, which is already
widely used in humans as antidiabetic drug, might be a promising candidate for the prevention
or treatment of colorectal cancer. On the other hand, type 2 diabetes mellitus, colorectal cancer,
and inflammatory bowel diseases are commonly occurring interrelated clinical problems. They share a
common basis influenced by disease-related inflammation, a process characterized by upregulation
of expression of common inflammatory cytokines along with TGFβ, TNFα, NF-κB, ROS and other
signaling molecules, leading to an imbalance in the intestinal microbiota. The intersection and the
converging of all these molecular pathways constitute a cross-talk, which affects the pathogenesis of
the above-mentioned chronic diseases. A treatment that can interfere with this cross-talk could be a
novel therapeutic target of interest in managing the three diseases. The authors are aware that some
aspects of the present work are still critical; these preliminary data will be refined in more sophisticated,
preplanned experiments.
4. Materials and Methods
4.1. Cell Culture
The human colon carcinoma cell line HT29 was obtained from the American Type Culture
Collection and was grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum, glutamine (4 mM), and penicillin (100 U/mL)/streptomycin (100 g/mL). Cell cultures
were maintained at 37 ◦C in 5% CO2 and 95% air. HT29 cells were plated at the approximate
density of 1 × 106 cells/dish in 10 cm2 culture dishes, 4 × 104 cells/well in two-well chamber glass
slides, and 1 × 104 cell/well in 96-well tissue culture plates. When cells reached approximately 60%
confluence, the medium was replaced with serum-free cell medium containing different concentrations
of metformin (0, 10, 25, and 50 mmol/L) and the cells were cultured for 24 and 48 h at 37 ◦C in 5%
CO2 and 95% air. The cells were trypsinized with 0.25% trypsin and 0.2 g/L EDTA, and harvested for
further studies. Metformin was purchased from Sigma Aldrich (Saint Louis, MO, USA; PHR 1084) and
was dissolved in sterile water at a stock dose of 1 M for further application.
4.2. Cell Counting
Cells were seeded at a density of 20,000/well and were counted at day one, two, and three
after plating. For counting, cells were detached from the wells by washing in a 0.25% trypsin and
0.2 g/L EDTA solution. Thereafter, 1 mL normal culture medium was added to stop the trypsinization;
a 500 µL cell suspension, to which 70 µL trypan blue was added, then, was transferred into a Burker
chamber for cell counting. The number of cells, expressed as number/mL, was determined by two
blinded observers.
4.3. Western Blot Analysis
Whole cell lysates were obtained from cultured cells, as described above, and extracted with
hypotonic buffer (50 mM Tris-Cl, pH 7.8, containing 1% Nonidet P40, 140 mM NaCl, 0.1% SDS, 0.1% Na
deoxycholate, 1 mM Na3VO4, and freshly added protease inhibitor cocktail). Lysates were then cleared
by centrifugation for 15 min in a refrigerated centrifuge at maximum speed, and then were immediately
boiled in SDS sample buffer. Forty milligrams of protein extract from each treatment condition was
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electrophoresed on SDS-PAGE and transferred to nitrocellulose membranes. The membranes were
blocked with 3% dry milk and 2% BSA in PBS-T, and incubated with the following antibodies (diluted
1:1000 overnight at 4 ◦C under agitation), mouse anti-human APAF-1, rabbit anti-human MAPLC3,
mouse anti-human NF-κB (Santa Cruz), mouse anti-human PARP-1 cleaved (Cell Signaling, Beverly,
MA, USA), mouse anti-human NRF-2 (Abcam, Cambridge, UK), and mouse anti-human Ki-67 (DAKO,
Glostrup, Denmark). After washing, the membranes were incubated with secondary HPR-conjugated
goat anti-mouse IgG antibody (1:5000) or HPR-conjugated goat anti-rabbit IgG antibody (1:5000)
(Thermo scientific, Waltham, MA, USA) for 30 min at room temperature. Immunoreactive proteins
were detected with ECL (Amersham, Little Chalfont, UK). Anti-mouse-β tubulin (Sigma Aldrich)
was used as loading control. Densitometry analysis was performed using a KODAK (Rochester, NY,
USA) Image Station 440 cf system), and semi-quantitative analysis was performed with NIH Image J
software. For each sample and marker, the band intensities were normalized to β-tubulin, and results
were expressed as the normalized treatment to control ratio.
4.4. Evaluation of Immunofluorescence by Confocal Microscopy
Cells were cultured in two-well chamber glass slides which were used for immunofluorescence
analysis to evaluate the expression of MAPLC3, APAF-1, PARP-1 cleaved, NRF-2, NF-κB, and Ki-67
proteins. Monolayered cells were fixed in 4% paraformaldehyde in PBS for 10 min. After a treatment
with 3% BSA in PBS for 30 min at room temperature, they were incubated with the primary antibodies
(mouse anti-human APAF-1, rabbit anti-human MAPLC3, mouse anti-human caspase-3 active,
mouse anti- human NF-κB, Santa Cruz mouse anti-human PARP-1 cleaved, mouse anti-human NRF-2,
Abcam mouse anti-human Ki-67, and DAKO), and diluted 1:25 in PBS containing 3% BSA for 1 h at
room temperature. After washing in PBS, the samples were incubated for 1 h at room temperature
with the secondary antibodies diluted by 1:20 in PBS containing 3% BSA (sheep anti-mouse FITC
conjugated, goat anti-rabbit TRITC conjugated, Sigma Aldrich). After washing in PBS and in H2O,
the samples were counterstained with 1 mg/mL DAPI in H2O and then mounted with antifading
medium (0.21 M DABCO and 90% glycerol in 0.02 M Tris, pH 8.0). Negative control samples were not
incubated with the primary antibody. The confocal imaging was performed under a Leica TCS SP2
AOBS confocal laser scanning microscope. Excitation and detection of the samples were carried out in
sequential mode to avoid overlapping of signals. Sections were scanned with laser intensity, confocal
aperture, gain, and black level settings kept constant for all samples. Optical sections were obtained
at increments of 0.3 mm in the z-axis and were digitized with a scanning mode format of 512 × 512
or 1024 × 1024 pixels and 256 grey levels. The confocal serial sections were processed with the Leica
LCS software to obtain three-dimensional projections. Image rendering was performed by Adobe
Photoshop software. The original green fluorescent confocal images were converted to greyscale and
median filtering was performed. An intensity value between 0 (black) and 255 (white) was assigned
to each pixel. Background fluorescence was subtracted and immunofluorescence intensity (IF) was
calculated as the average for each selected area. The fluorescence intensity at the selected areas, linearly
correlated with the number of pixels, and was quantitatively analyzed using the standard imaging
analysis software of an NIS-Elements System. Each sample was assigned a code number and score,
referred to as the Immunofluorescence Intensity Score (IFIS), which was determined by an observer
who was blind to tissue groups during the analysis [49].
4.5. Flow Cytometry Analysis
The apoptotic status of HT-29 cells was evaluated by measuring the exposure of
phosphatidylserine on the cell membranes using Annexin V-fluorescein isothiocyanate (Annexin
V-FITC) and propidium iodide (PI) staining [50]. The BD Pharmingen Annexin V-FITC Apoptosis
Detection Kit I (BD Biosciences, Frankrin Lakes, NJ, USA) was used for the apoptosis assay. HT-29
cells were plated in a 24-well plate (1 × 106 cells mL−1), and after a 24 h incubation, the cells
were treated with graded concentrations of metformin (0, 10, 25, and 50 mmol/L) for 24 and 48 h,
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and harvested. After centrifugation, the cell pellets were washed twice with cold phosphate-buffered
saline (PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, pH 7.4) and suspended in 100 µL of 1×
binding buffer (10 mM Hepes/NaOH, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4). The cells were incubated
with 5 µL Annexin V-FITC and 10 µL PI at room temperature for 15 min in the dark. After the
incubation, 400 µL of 1× binding buffer was added to each tube. The cells were analyzed immediately
by Epics XL-MCL Flow Cytometry (Beckman Coulter, Cassina de Pecchi, Italy).
4.6. Statistical Analysis
All experiments were performed in triplicate. Data were expressed as means ± standard
deviation. Statistical comparisons of results were made using analysis of variance (ANOVA). Significant
differences (p < 0.05) between the means of control and metformin treated cells were analyzed by a
Student’s t-test.
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